The heterogeneity of high-grade glioma tumors is defined by four clinically significant subtypes based on the signatures of key genes, resulting in the identification of the four following malignant phenotypes5 (Figure 1):(1)Neural stem cell-like (NPC-like): Characterized by stem cell markers (CD133/prominin-1, Oct4/POU5F1, Nanog, SOX2, NESTIN, and CD44) and neuronal differentiation pathways and predominantly localizes to the tumor core. This evidence concerns the gene PROM1 and central nervous system cancer.